Bacci G, Ferrari S, Ruggieri P, Biagini R, Fabbri N, Campanacci L, Bacchini P, Longhi A, Forni C, Bertoni F
Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy.
Acta Orthop Scand. 2001 Apr;72(2):167-72. doi: 10.1080/000164701317323426.
Between April 1990 and December 1994, we treated 24 patients with telangiectatic osteosarcoma (TO) of the extremities with neoadjuvant chemotherapy using 2 protocols. Surgery consisted of limb salvage in 21 patients and amputation or rotation plasty in 3. The histologic response to chemotherapy was good (90% or more tumor necrosis) in 23 patients, of whom 12 had total necrosis. With a mean follow-up of 74 (60-96) months, 20 patients remained continuously free of disease and 4 relapsed with lung metastases. There were no local recurrences. Comparing these results to the ones achieved in 269 contemporary patients with conventional osteosarcoma of the extremities using the same protocols for chemotherapy, we found a significantly better histologic response to chemotherapy (96% vs 68% of good histologic response; p = 0.004) and disease-free survival (83% vs 55%; p = 0.01) in the TO group. We conclude that TO, once considered a lethal tumor, seems to be even more sensitive to chemotherapy than conventional osteosarcoma, and that most of these patients may be cured without amputation.
1990年4月至1994年12月期间,我们采用两种方案对24例四肢毛细血管扩张性骨肉瘤(TO)患者进行了新辅助化疗。手术方式包括21例患者行保肢手术,3例行截肢或旋转成形术。23例患者对化疗的组织学反应良好(肿瘤坏死率达90%或更高),其中12例完全坏死。平均随访74(60 - 96)个月,20例患者持续无病生存,4例出现肺转移复发。无局部复发。将这些结果与269例采用相同化疗方案的同期四肢传统骨肉瘤患者的结果进行比较,我们发现TO组对化疗的组织学反应(良好组织学反应率分别为96%和68%;p = 0.004)和无病生存率(分别为83%和55%;p = 0.01)明显更好。我们得出结论,TO曾被认为是一种致命肿瘤,但其似乎比传统骨肉瘤对化疗更敏感,并且这些患者中的大多数可能无需截肢即可治愈。